Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.48 |
| ▸ | GABRE | P78334 | 6/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31271664 | 0.94 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL5495291 | 0.94 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL27144994 | 0.84 | LCK (0.55) | ALDH1A1GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL31413462 | 0.84 | LCK (0.55) | ALDH1A1GABRG2GABRB3GABRA5GABRA1 | |
| SCHEMBL22395353 | 0.83 | GABRA1 (0.49) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL21885348 | 0.83 | ALOX15 (0.50) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL30712292 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL2201127 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL30712301 | 0.82 | GABRA1 (0.59) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 | |
| SCHEMBL1808295 | 0.79 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-111630051-B | Olefin spiro compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3704106-B1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2022-09-08 | — | — | US | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | MSD K.K. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1939194-A1 | BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | ALDH1A1 3511/4885SMN1; SMN2 1837/4885GABRG2 703/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ALDH1A1 2142/4885SMN1; SMN2 2773/4885GABRG2 608/4885 |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | ALDH1A1 684/4885SMN1; SMN2 1242/4885GABRG2 2317/4885 |
| US-20220281833-A1 | SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | ALDH1A1 985/4885SMN1; SMN2 1235/4885GABRG2 3198/4885 |
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | ALDH1A1 1003/4885SMN1; SMN2 969/4885GABRG2 3956/4885 |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | ALDH1A1 1437/4885SMN1; SMN2 4089/4885GABRG2 2267/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | ALDH1A1 1563/4885SMN1; SMN2 4067/4885GABRG2 3982/4885 |
| US-20090264426-A1 | Bicyclic aromatic substituted pyridone derivative | PYCR1, CHRM1, MTR | ALDH1A1 1755/4885SMN1; SMN2 2642/4885GABRG2 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.